Skip to main content
Delfa

← All trials/NCT06893211

TABFAT

Active not recruitingPhase 2

Effect of Tirzepatide on Brown Adipose Tissue in Obesity

Effect of Tirzepatide-Induced Weight Loss on Adipose Tissue in Obesity

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

1

Recruiting sites

-

Estimated enrollment

35

Study population

Obesity / overweight

Eligibility highlights

•Female

Primary endpoints

•Brown Adipose Tissue Activity and Volume•Molecular Markers of Browning in Subcutaneous White Adipose Tissue

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT06893211
Org study ID0120-56/2024-2711-7

Timeline

Milestones

Study start2025-03-18actual
Study first posted2025-03-25actual
Last update posted2025-05-15actual
Primary completion2025-11estimated (month precision)
Study completion2025-12estimated (month precision)

Assets

Investigational agents

Tirzepatide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age20 Years
Maximum age50 Years
SexFemale
Healthy volunteersNot accepted

Inclusion criteria

•Female sex
•Age between 18 and 50 years
•BMI between 30 kg/m² and 40 kg/m² at pre-screening
•Prior comprehensive non-pharmacological and non-surgical management of obesity, including a history of at least 12 months of intensive lifestyle intervention with a maximum weight reduction of less than 5%
•Stable body weight within the three months preceding study enrollment (defined as weight fluctuations within 5%)
•No prior pharmacological or surgical interventions for obesity
•Euthyroid state
•Eumenorrhea or Oligomenorrhea
•Ability to comprehend the study objectives and procedures
•Willingness to provide informed consent and to comply with the study protocol, including the use of highly effective contraception during the study period, with signed consent and agreement provided in duplicate
•Commitment to use highly reliable contraception and absence of plans for pregnancy within the 8 months following enrollment

Exclusion criteria

•Pregnancy or lactation
•Postmenopausal
•Amenorea
•Type 2 diabetes
•Reliance on natural contraception methods
•Non-compliance with previous therapeutic regimens
•Personal history of malignancy
•Personal or family history of medullary thyroid carcinoma
•Personal history of pancreatitis
•Personal history of cholelithiasis
•Personal history of major depressive episodes or suicidal ideation
•Personal history of acute coronary events or hemodynamically significant coronary artery disease
•Psychiatric disorders
•Current treatment with sympathomimetics or sympatholytics
•Excessive alcohol consumption

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition
3
Other (unclassified)
3

Weight & body composition

3 endpoints
Primary/protocol endpoint

Change in Brown Adipose Tissue Activity and Volume

Time frame:Baseline to Week 24

change from baseline, improvement

Primary/protocol endpoint/low confidence

Change in Molecular Markers of Browning in Subcutaneous White Adipose Tissue

Time frame:Baseline to Week 24

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Correlation Between Different BAT Assessment Methods

Time frame:Baseline and Week 24

descriptive

Other (unclassified)

3 endpoints
Secondary/protocol endpoint/low confidence

Change in Resting Energy Expenditure

Time frame:Baseline to Week 24

change from baseline, descriptive

Secondary/protocol endpoint/low confidence

Association Between Changes in Resting Energy Expenditure, Metabolic Health Markers, and Thermogenic Adipose Tissue

Time frame:Baseline to Week 24

descriptive

Secondary/protocol endpoint/low confidence

Association Between Resting Energy Expenditure, Metabolic Health Markers, and Thermogenic Adipose Tissue

Time frame:Baseline

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.